Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome.
Bsteh G, Hoepner R, Gernert JA, Berek K, Gradl C, Kliushnikova D, Damulina A, Traxler G, Föttinger F, Habernig S, Krajnc N, Betancourt AXL, Ponleitner M, Zrzavy T, Deisenhammer F, Di Pauli F, Havla J, Khalil M, Kümpfel T, Wipfler P, Chan A, Berger T, Hammer H, Hegen H.
Bsteh G, et al. Among authors: khalil m.
Eur J Neurol. 2025 Jan;32(1):e16587. doi: 10.1111/ene.16587.
Eur J Neurol. 2025.
PMID: 39686558
Free PMC article.